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Characterization of an immunizationinduced broadly neutralizing antibody in macaques against ebolaviruses highlights the fusion loop region of the viral glycoprotein as a promising vaccine target.
INTRODUCTION
Members of Filoviridae family (filoviruses) are among the deadliest viruses with no approved treatments or vaccines available for human use. There are five known ebolavirus species: Ebola (EBOV), Sudan (SUDV), Bundibugyo (BDBV), Reston (RESTV), and Taï Forest (TAFV) viruses, a cuevavirus, and two marburgviruses: Marburg virus (MARV) and Ravn virus (RAVV) (Kuhn et al., 2014) . Since 1967 multiple outbreaks of MARV, SUDV, and BDBV have been recorded and in the recent Ebola virus disease epidemic in 2014, caused by the Zaire EBOV, the virus seems to have mutated to infect humans more efficiently (Diehl et al., 2016) . Current vaccines and immunotherapeutics advancing through late stage development are specific for EBOV (Zaire). Thus, broadly protective vaccines and antibody therapeutics for filoviruses are critically needed.
Filovirus entry is mediated by the trimeric filovirus glycoproteins (GPs), which consist of disulfide-linked GP1 and GP2 subunits, with GP1 forming a chalice-like structure wrapped around by GP2 (Lee et al., 2008; Zhao et al., 2016) . GP2 and the N terminus of GP1 form the chalice base. The receptor binding site (RBS) is positioned on the GP1 apex and largely concealed by a glycan cap and a highly glycosylated and disordered mucinlike domain (MLD) . Filoviruses enter the endosomes via micropinocytosis, during which the cysteine proteases cathepsin B and L cleave off the MLD and the glycan cap, exposing the RBS and allowing GP1 to interact with its endosomal receptor, Niemann Pick C1 (NPC1) (Bornholdt et al., 2016a; Miller et al., 2012; Wang et al., 2016a) . Upon binding to NPC1, and in response to an undefined trigger, GP2 is proposed to undergo major rearrangements to insert its internal fusion loop (IFL) into the endosomal membrane and initiate viral fusion (Lee and Saphire, 2009) .
Three mechanisms of neutralization have been postulated for ebolaviruses: inhibition of cathepsin-mediated cleavage, blockade of NPC1 binding, and mechanical interference with the structural rearrangements of GP2 required for fusion (Saphire and Aman, 2016) . The best characterized neutralizing epitope within EBOV GP is the base epitope, consisting of residues at the GP1-GP2 interface, which is recognized by the monoclonal antibody (mAb) KZ52 (Lee et al., 2008) and with a slightly different angle by two ZMapp components, c2G4 and c4G7 (Murin et al., 2014) . However, these base binders only neutralize EBOV. A similar base binder, 16F6, was also reported to neutralize SUDV only (Dias et al., 2011) . Recently, we and others have identified several cross-neutralizing epitopes within the RBS (Howell et al., 2016; Keck et al., 2015) and the glycan cap (Bornholdt et al., 2016b; Flyak et al., 2016; Holtsberg et al., 2015) , suggesting that development of broadly neutralizing antibodies (bNAbs) and cross-protective vaccines might be feasible.
Here, we report an ebolavirus bNAb, called CA45, elicited by immunization of nonhuman primates (NHPs) , that binds to a conserved epitope positioned within the IFL. CA45 potently neutralizes EBOV, SUDV, and BDBV, the only ebolaviruses known to cause lethal disease in humans, and protects rodents from EBOV and SUDV infection. Furthermore, a cocktail of CA45 with the RBS-binding mAb FVM04 fully protects guinea pigs from lethal EBOV and ferrets from BDBV infection. This study has further important implications for vaccine development. Unexpectedly, we found that a proteolytically remodeled GP resembling the endosomal form of GP generated by host cathepsins (cleaved GP, GP CL ) binds with >10 6 -fold higher affinity to the CA45 germline precursor compared to full-length GP, indicating that similar modification of vaccine immunogens could potentially enhance the elicitation of CA45-like bNAbs.
The isolation of bNAbs against ebolavirus from vaccinated NHPs, their superior protective efficacy, and the prospect of germline targeting by vaccine re-design strongly support the premise of pan-ebolavirus antibody cocktails for therapy and a pan-ebolavirus vaccine for prevention.
RESULTS

Isolation of Ebolavirus Cross-reactive mAbs
A cynomolgus macaque (NHP #20667) was immunized three times with a trivalent GP cocktail consisting of EBOV, SUDV, and MARV GPDmuc (ectodomain lacking MLD) in a previous study (Keck et al., 2015) . Serum from this macaque (4 weeks after the third immunization) neutralized EBOV, SUDV, and BDBV (Figure 1A) , suggesting that ebolavirus cross-reactive B cells may exist in this animal. Using an optimized fluorescently labeled memory B cell surface marker cocktail (Sundling et al., 2012; Wang et al., 2016b) Tables S1 and S2. About 0.5% of the memory B cell of this macaque was GP specific, with $0.06% being EBOV/SUDV cross-reactive, accounting for $10% of GP-specific memory B cells (Table S1) . We sorted out 29 ebolavirus family GP cross-reactive memory B cells, of which 17 had paired HCs and LCs. Of these, 12 clones were expressed as full-length IgG1 for ELISA assay (Table S1 ). More than 90% of the clones (11/12) bound both EBOV and SUDV GPDmuc (Figure 1C ), validating the sorting precision. Analysis of the HC and LC variable regions (V H and V L ) along with the HC and LC complementarity determining region 3 (CDRH3 and CDRL3) revealed that 4 of 11 clones were related to each other and/or to clones identified by yeast display method in our previous study (Keck et al., 2015) , while the remaining 7 were unique clones (Table S2 ). In a neutralization assay with recombinant vesicular stomatitis virus (rVSV) pseudotyped with either EBOV or SUDV GP, we found that $30% (4/11) of the GP cross-reactive clones neutralized rVSV with either GP. Only one clone, CA45, neutralizing both EBOV and SUDV, was identified as a bNAb (Table S2) .
Binding and Functional Characterization of CA45
Given that filovirus receptor interaction and membrane fusion occurs in the acidified endosomes, we examined CA45 binding to GP ectodomains (GPDTM) at both acidic and neutral pH by ELISA. CA45 strongly bound to GPDTM of EBOV, SUDV, BDBV, and moderately to RESTV at both pH (Figure 2A ). The reactivity of CA45 was moderately enhanced under acidic pH condition for all GPDTM. We also tested the binding of CA45 to cathepsin-cleaved GP (GP CL ), the form that interacts with NPC1 in the endosomes and mediates the membrane fusion. CA45 bound to EBOV GP CL about 23-, 14-, and 7-fold better than to GPDTM at pHs 7.5, 5.5, and 4.5, respectively (Figure 2A ). In contrast, CA45 did not bind soluble GP (sGP), the product of the unedited EBOV GP gene (residues 1-295 followed by a unique C-terminal tail) (Figure 2A) . These data indicate that CA45 binding does not require the MLD or the glycan cap and that removal of these domains reduces the steric constraints on CA45 binding.
BioLayer interferometry (BLI) was used to evaluate the kinetics of CA45 binding to GPDTM and EBOV GP CL (Figure 2B) . The apparent K D values for GPDTM were determined to be approximately 10.6 nM for EBOV, 3.3 nM for SUDV, 1.2 nM for BDBV, and 161 nM for RESTV, respectively. Consistent with the ELISA data, CA45 bound EBOV GP CL with higher affinity (sub picomolar) than EBOV GPDTM.
We then tested the ability of CA45 to neutralize a replication competent rVSV pseudotyped with filovirus GP expressing GFP (rVSV-GP-GFP). CA45 potently neutralized rVSV-GP-GFP for EBOV, SUDV, BDBV, and to a lesser extent RESTV, but not TAFV or LLOV ( Figure 2C ). We confirmed that the neutralization is due to inhibition of cellular entry via a single-round infection assay using a VSV-GP-expressing luciferase (rVSV-Luc), in which CA45 potently cross-neutralized rVSV-Luc for EBOV, SUDV, and BDBV ( Figure 2C ). To examine whether CA45 could neutralize the cathepsin-primed form of EBOV that mediates membrane fusion, we treated rVSV-GP viruses with thermolysin to generate particles displaying GP CL . Interestingly, the neutralizing potency of CA45 versus GP CL was dramatically higher (100-to 1,900-fold lower IC 50 ) compared to full-length GP (Figure 2C) , consistent with the strikingly higher binding affinity of CA45 to GP CL versus GPDTM. In sharp contrast, KZ52 failed to neutralize cleaved EBOV ( Figure 2C ). CA45 neutralization breadth was further confirmed in plaque reduction neutralization tests using the authentic ebolaviruses ( Figure 2C ). As a reference, all reported and characterized ebolavirus mAbs, along with CA45, are provided in Table S3 .
The contrast between CA45 and KZ52 in neutralization capacity against EBOV bearing cleaved GP CL suggested that KZ52 might act upstream of cathepsin cleavage and CA45 at a step downstream. We therefore sought to elucidate the step(s) of entry affected by CA45 and KZ52. As expected, neither CA45 nor KZ52 had any effect on the binding of GP CL to NPC1 (Figure S1A ). We then examined the effect of CA45,KZ52, and the EBOV mAb100 on cathepsin L cleavage of GPs by western blot. CA45 showed partial inhibition of cathepsin cleavage, evidenced by the accumulation of partially cleaved GP species and the weaker band of completely cleaved GP (GP CL ) compared to the control antibody, while mAb100 exhibited nearly complete inhibition as previously reported , and KZ52 moderately inhibited the GP cleavage (Figure S1B) . Using a live-cell imaging assay (Spence et al., 2016) , we further evaluated whether CA45 blocks fusion triggering, an early stage of virus-cell membrane fusion. As shown in Figure S1C , viral fusion triggering, indicated by membrane lipid mixing, was not significantly inhibited by CA45, in contrast to KZ52. Furthermore, no significant difference in co-localization of internalized virus particles with NPC1 was observed following incubation of virus and cells with CA45, indicating that CA45 does not affect receptor binding. Collectively, these data suggest that CA45 might block virus entry at two stages: (1) by inhibiting cathepsin cleavage and (2) by inhibiting a later stage that is after receptor binding but prior to productive fusion of the viral and the endosomal membranes.
A Primary Role for CA45 HC in GP Binding Analysis of the V H and V L regions of CA45 inferred their cynomolgus macaque germline precursors as IGHV4S17 and IGKV1-5, respectively ( Figure 3A ). CA45 had a moderate level of somatic hypermutation (SHM) (9.9% nt and 14% aa for V H , and 7.5% nt and 14% aa for V L , respectively) and a 19-residue CDRH3 loop (Figure 3A) (Table S4) . It is of note that there is one amino acid deletion in CDRH1 (G30) and that the CDRH3 is flanked by two negatively charged residues, D95 and D101, and contains eight hydrophobic residues (F, I, V, W, and L) (Figure 3A) , which might impart molecular recognition of CA45.
We performed alanine-scanning mutagenesis of CA45 CDRs to examine the role of CDR residues in CA45-GP interaction (Figures 3B and 3C and Figure S2) . Interestingly, only mutations in CDRH1 and CDRH3 caused dramatic decrease of CA45 binding to GP, while other mutations had little impact ( Figures 3B and 3C and Figure S2 ), implying that CA45 HC plays a major role in GP recognition and LC plays a minor role. Most residues in CDRH1 and CDRH3 critical for binding are either highly hydrophobic or negatively charged ( Figure 3C ), suggesting that hydrophobic interactions and salt bridges might be heavily involved in (legend continued on next page) the CA45-GP recognition interface. The neutralization afforded by the mutants closely mirrored the binding pattern.
We generated germline reverted CA45 (CA45-H GL L GL ) based on the inferred germline sequences to examine the contribution of SHM to CA45 function. CA45-H GL L GL showed very weak binding for GPDmuc and no binding to BDBV GPDTM (Figure 3D and Figure S3 ) but sub-picomolar affinity to GP CL , indistinguishable from the mature CA45. These data suggest that GP steric constraints that restrict CA45 germline precursor from accessing its cognate GP epitope can be eased by the removal of the MLD and glycan cap. Consistent with a major role of CA45 HC in GP recognition, CA45-H m L GL , a semi-reverted CA45 containing mature HC and germline LC, bound EBOV GPDmuc with similar affinity as mature CA45 but exhibited 12-and 35-fold poorer affinity to GPs of SUDV and BDBV, respectively ( Figure 3D ).
CA45-H GL L GL , failed to neutralize pseudotyped rVSV-GPs, while the semi-reverted CA45-H m L GL showed detectable but severely reduced neutralizing potency ( Figures S3L-S3N ), indicating that the maturation of CA45 LC is important for its function. Furthermore, CA45-H m L GL retained potent neutralizing activity toward rVSV-EBOV CL (IC 50 $0.1 nM), while CA45-H GL L GL failed to exhibit significant neutralization ( Figure S3O ), suggesting that affinity maturation of CA45 HC is critical for rVSV-EBOV CL neutralization. The failure of CA45-H GL L GL to neutralize rVSV-EBOV CL despite its high binding affinity for GP CL (at neutral pH) suggested that CA45-H GL L GL might fail to bind GP CL in the acidic environment of endosomes. Consistent with this hypothesis, the binding of CA45-H GL L GL to GP CL decreased by over 2 logs at pH 4.5 as compared to at pH 7.5 ( Figure S3P ), indicating that maturation of CA45 is needed for GP CL binding in the endosomes. The mature CA45 lacks V H residue G30 that exists in the germline CDRH1, suggesting that the deletion of G30 occurred during affinity maturation and might be critical for CA45 function. A mature CA45 variant with a glycine insertion at this position (CA45-G30) showed severe reduction in binding to GP and neutralizing activity (Figures S3Q and S3R) , with slightly reduced potency toward EBOV CL (Figure S3S) , suggesting that GP CL could readily recognize CA45-G30, the less mature form of CA45.
Epitope Mapping of CA45
To determine the GP epitope surface recognized by CA45, we evaluated the competition between CA45 and a series of EBOV mAbs with known epitopes by using BLI. CA45 did not compete with the glycan cap binder 13C6, RBS binder FVM04, or with FVM02, which binds to the tip of the IFL (Table S5) . However, CA45 strongly competed with KZ52 (Table S5 ), suggesting that their epitopes are closely positioned, perhaps at the GP base.
To identify the GP residues critical for CA45 binding, we evaluated the binding of CA45 and two control mAbs against a shotgun mutagenesis alanine-scanning library of EBOV GP in which 641 of 644 GP residues were individually mutated. The epitope mapping identified residue R64 within the N terminus of GP1, in addition to Y517, G546, and N550 within the IFL of GP2, as critical for CA45 binding ( Figures 4A and 4B ). Compared to wild-type GP, alanine substitutions at these residues reduced CA45 binding by 98%, 96%, 89%, and 78%, respectively, while the binding of control antibodies, FVM04 and FVM09, to these mutants was not reduced (Figure 4B) .
These four residues are highly conserved among GPs of all ebolaviruses ( Figure 4C ). R64 is located within the b3 strand at the N terminus of GP1 and is identical between Kikwit, Mayinga, and Makona strains of EBOV, while other ebolaviruses have a lysine residue at this position. Y517 and G546, positioned in strands b19 and b20 within the IFL, are identical among all ebolavirus species ( Figure 4C ). N550, located in the b20-a3 (HR1-A) loop, is also conserved among all filoviruses and is shared by the KZ52 epitope (Davidson et al., 2015) . In contrast, except for the residues within b20 and b20-a3 loop, MARV GP shows little homology in this region (Figure 4C) , consistent with the lack of CA45 binding to MARV GPs. The key residues are clustered closely within the base of the GP trimer structure ( Figure 4D ). In addition, ala substitution of residue K190 ( Figure 4D ) also reduced CA45 binding by 67%, suggesting that K190 might also be important for CA45 binding.
To further evaluate the conservation of CA45 epitope, we retrieved sequences of over 1,300 ebolavirus GP variants from the NCBI Virus Variation Database (https://www.ncbi.nlm.nih. gov/genomes/VirusVariation) , which contains all the ebolavirus GP variants deposited in GenBank, including strains circulated in the 2014 West Africa outbreak (Carroll et al., 2015; Park et al., 2015) . We analyzed 231 unique GP variants and found that the four epitope residues, R64, Y517, G546, and N550, were all conserved without variations (Table S6) . We also generated additional mutations within the key CA45 contact sites to evaluate their impact on CA45 binding, based on GP sequence homology in this region shown in Figure 4C . Interestingly, only Y517I showed severely reduced binding to CA45, whereas most of the mutations enhanced CA45 binding (Figure 4E) , and N550Q retained similar binding ( Figure 4E ), compared to the wild-type GP. The above stated GP variant sequence analysis data revealed no mutation at residue Y517, suggesting that alteration of this residue cannot be tolerated. Consistent with this notion, Y517A mutation in the context of a GP-pseudotyped lentivirus strongly reduced viral replication (B. Doranz, personal communication). Taken together, the CA45 epitope residues on GP are highly conserved across the ebolavirus family.
The key CA45 contact sites largely overlap in the overlay of GPDmuc (5JQ3) and GP CL (5HJ3) structures (Figure S4A) , suggesting that there is no significant difference in their (B) Kinetics of CA45 binding analyzed by BLI. On-rate (k on ), off-rate (k off ), and K D values for each GP ligand are shown below the sensograms. (C) CA45-mediated neutralization of ebolaviruses: (far left) replication-competent rVSV-GP-GFP; (left) replication-incompetent rVSV-GP-Luc; (middle) thermolysin cleaved rVSV-GP-GFP (subscript CL) in comparison to non-cleaved rVSV-GP-GFP; and (right) authentic ebolaviruses (EBOV,SUDV, and BDBV). Data in (A) and (C) are represented as mean ± SEM. Also see Figure S1 and Table S3 . configurations on cathepsin-cleaved GP and the uncleaved GPDmuc. However, the bulky residues D192, F193, and F194, referred to as the DFF lid, clearly appear over the CA45 epitope in GPDmuc structure, while being disordered in GP CL (Figure S4A) . These residues, were reported to block access to the binding pocket for toremifene, a small molecule inhibitor of EBOV membrane fusion (Zhao et al., 2016) (Figure S4B ). Interestingly, ala substitution of D192, F193, and F194 increased CA45 binding to 170%, 182%, and 224% of wild-type GP, respectively ( Figure S4C ), suggesting that the DFF lid might interfere with CA45 binding to GP. Displacement of the DFF lid in GP CL might allow CA45 and its germline precursor to readily access the cognate epitope.
We cultured VSV-EBOV GP replication competent virus in the presence of CA45 for four passages to isolate CA45 escape variants. Ten escape clones were plaque purified and sequenced. All escape clones contained two mutations, A101V and K588R, with two variants harboring a third mutation of either N643D or A654T in the GP stalk (Figures S5A and S5B) . These mutants showed strongly reduced CA45 binding (Figure S5C) or neutralization ( Figure S5D ). Interestingly, none of the CA45 GP contact residues identified by alanine-scanning mutagenesis were mutated in escape variants, suggesting that mutations of these residues may be detrimental for viral fitness. Neither A101 nor K588 exposes well on the GP surface, while the orientations of N643 and A654 are not clear in the existing crystal structures of GP. The combined mutations likely have a structural impact on the CA45 binding site. In the GP ala-scanning study, the single mutants of A101S, K588A, N643A, or A654S did not show any significant change in CA45 binding (Figure S5E) , suggesting that only combinations of these mutations can lead to escape by altering the epitope environment ( Figure S5B ), as both A101 and K588 are in proximity of R64 and Y517, which are critical for CA45 binding ( Figure S5B ). As expected, the CA45 escape mutants were readily neutralized by the RBS binding mAb FVM04 ( Figure S5F ).
Electron Microscopy Reconstruction of the GP-CA45 Complex
To further understand how CA45 interacts with GP, we derived a 3D negative stain EM reconstruction of the CA45 Fab-EBOV GPDTM complex ( Figure 5A and Figure S6 ). CA45 approaches GP with a nearly perpendicular angle and binds the GP region proximal to the IFL ( Figure 5B ). A homology model of CA45 was docked to orient the HC and revealed that the CDRH1 and CDRH3 loops interact closely with the IFL-surrounding GP residues ( Figure 5C ). In this CA45-GP model, CA45-contacting GP residues R64, Y517, G546, and N550 ( Figure 5C , shown in -6152) . KZ52 (blue) (PDB: 5HJ3) also contacts similar residues as c2G4. CA45 Fab (gray) has significant overlap with these three EBOV antibodies, but with its shifted angle of approach, may confer breadth of neutralization. Also see Figure S6 . dark blue) face toward the CA45 CDRs, consistent with the GP alanine-scanning data ( Figure 3C ).
Mirroring the binding competition analysis, the EM data showed that KZ52 Fab epitope overlaps with that of CA45, but at a different angle, and contacts some non-conserved GP residues ( Figure 5D ). Conversely, CA45 binds to a more conserved region of filovirus GP ( Figure 5D ). Thus, our data reveal the molecular basis for the expanded neutralization breadth of CA45, which targets a conserved epitope proximal to those of the EBOV-specific antibodies KZ52, c2G4, and c4G7. (Figure 5E ).
In Vivo Protection against EBOV and SUDV in Mice and Guinea Pigs Post-exposure in vivo efficacy of CA45 was first tested in mouse models of EBOV and SUDV. BALB/c mice were infected with mouse-adapted EBOV followed by intraperitoneal (i.p.) injection of CA45 (10 to 0.5 mg/kg) or PBS as control, 2 days post infection (dpi). Significant protection from lethality and much lower weight loss was observed at all CA45 dose levels as compared to the control group (Figure 6A) .
We then tested the efficacy of CA45 in a SUDV model by using mice deficient for the IFNa receptor (B6.129S2-Ifnar1tm1Agt/ Mmjax) (Brannan et al., 2015) . In multiple experiments, mice were challenged with SUDV (1,000 pfu) and treated by a single i.p. injection of mAbs at 1 dpi. CA45 (10 mg/kg) protected five out of six animals from lethal infection, which exhibited an average of <6% weight loss as compared to 28% in the PBS group (Figure 6B, upper panel) . We previously demonstrated that RBS binding mAb FVM04 afforded partial protection in this model (Howell et al., 2016) . To examine whether combining a receptor blocker with a fusion inhibitor might yield greater efficacy, we combined FVM04 and CA45 at 5 mg/kg each (Figure 6B upper panel) or 5 mg/kg of FVM04 plus 2.5 mg/kg of CA45 ( Figure 6B , lower panel). Both combinations provided 100% protection in independent experiments. Interestingly, cocktail-treated mice showed no weight loss or other signs of disease, unlike those treated with single mAbs ( Figure 6B ). Furthermore, we tested CA45 or FVM04 alone or in combination in a stringent guinea pig model of EBOV infection, in which a single dose of mAb was delivered at 3 dpi. Guinea pigs infected with 1,000 LD 50 of guinea-pigadapted EBOV (GPA-EBOV) were treated with either FVM04 or CA45 at 5 mg/animal, a combination of the two mAbs at 2.5 or 5 mg each, or PBS. All cocktail-treated animals survived the infection with no sign of disease or weight loss (Figure 6C ), while PBStreated animals all died with a mean time to death (MTD) of 7.5 days and 21% body weight loss. Monotherapy with 5 mg of FVM04 or CA45 provided partial protection of 17% (MTD: 11.5 days) and 50% (MTD: 20.5 days) of the animals, with maximal weight loss of 9.2% and 1.2%, respectively ( Figure 6C ). The protection afforded by either monotherapy or combination was significantly better than that afforded by PBS treatment in guinea pigs (p = 0.0018 and p < 0.0001, respectively). Furthermore, combination therapy was significantly better than monotherapy with CA45 (p = 0.0079) or FVM04 (p < 0.0001). These data, combined with the lack of weight loss in cocktail-treated groups, indicate that combining the two mAbs strongly enhances the efficacy.
We then evaluated whether CA45 alone could also protect against SUDV in guinea pigs. As shown in Figure 6D , similar to our previous data with FVM04 (Howell et al., 2016) , 5 mg CA45 at 3 dpi protected all animals from lethal infection with GPA-SUDV without any weight loss, while all control guinea pigs died within 14 dpi (p < 0.0001) and lost up to 25% of their body weight ( Figure 6D ).
Protective Efficacy in Ferrets
A ferret model was recently developed that exhibits many features of filovirus disease in humans (Kozak et al., 2016) . Since guinea pig studies indicated that a combination of CA45 and FVM04 is optimal for effective control of EBOV infection, we tested this cocktail in the BDBV ferret model. A group of two male and two female ferrets were infected with 253 TCID 50 of BDBV and treated at 3 and 6 dpi with 20 mg of each antibody by i.p. injection. Two infected ferrets received PBS at the same time points as control. All four treated animals survived with no clinical signs of disease (Figures 7A and 7B) . One animal (888M) who experienced an unrelated accident on 21 dpi, leading to paralysis of both hind legs and failure to reach food and water, was euthanized on 22 dpi. Among the treated animals, the male ferrets (808M and 888M) showed steady weight gain and no detectable virus in the blood, while the female animals exhibited less weight gain with moderate and transient viremia at $10 4 GEQ/mL on day 6. Control animals succumbed to infection 7 dpi and displayed very high viremia ($10 10 GEQ/mL) ( Figures 7C and   7D ). High viral load was also detected in oral, nasal, and rectal swabs of both control animals but none of the treated ferrets ( Figures 7E-7G ).
Blood chemistry analysis showed a drastic rise in circulating levels of alkaline phosphatase, alanine aminotransferase, total bilirubin, blood urea nitrogen, and potassium in control animals ( Figure 7H-7L) , similar to the disease course in humans and NHPs (Feldmann and Geisbert, 2011) , while these parameters remained unaffected in treated animals ( Figure 7H-7L) . Complete blood count (CBC) analysis showed a drop in white blood cell count, and a drastic reduction in total lymphocyte and platelet counts, which rapidly rebound only in treated animals ( Figure S7 ). The complete results of the blood chemistry and CBC analysis are shown in Figure S7 . Groups of two male and two female ferrets (denoted with M or F suffix to animal number) were infected with 253 TCID 50 of BDBV followed by i.p. injection at 3 and 6 dpi with 20 mg each of CA45 and FVM04. Two control animals (780M and 727F) received PBS only. Protection data are shown as percent survival (A), clinical score (B), weight change (C), viral burden in blood (D), and tissue swabs (E-G), as well as blood chemistry markers (H-L). Also see Figure S7 .
DISCUSSION
In this study, we identified a novel bNAb (CA45) from immunized NHP B cell repertoire, which targets a key site of vulnerability within the highly conserved ebolavirus IFL. Recently, a mousederived bNAb targeting ebolavirus IFL (Furuyama et al., 2016) , as well as bNAbs targeting the fusion peptides of HIV-1 envelope (Env) GPs (Kong et al., 2016; van Gils et al., 2016) and influenza A hemagglutinins (Joyce et al., 2016; Kallewaard et al., 2016) , have been reported. The progressively emerging bNAbs specific for fusion peptides of various viruses implies mechanistic convergence of host immunity against a conserved functional vulnerability. CA45 neutralizes four out of five ebolaviruses and displays protective efficacy in animal models of Ebola, Sudan, and Bundibugyo viruses. CA45 exhibits unique features with respect to its pattern of reactivity to various forms of GP, properties of its germline precursor, and its conserved epitope that have important implications for the design of pan-ebolavirus vaccines and therapeutics.
CA45 was isolated from cynomolgus macaque, a species with Ig gene composition highly homologous to humans, suggesting that immunization can elicit bNAbs targeting conserved and vulnerable ebolavirus epitopes in primates including humans. Our findings indicate that memory B cells that encode ebolavirus bNAbs are of low frequency, accounting for $1% of the GP-specific and $0.005% of total memory B cells, consistent with the observation in previous studies that the protective responses to prototypical ebolavirus vaccines are mostly strain specific (Mire et al., 2013) . This might relate to low precursor frequency and/or inefficient activation of such precursors by the vaccine. Indeed, we observed very poor binding of the CA45 germline precursor (CA45-H GL L GL ) to wild-type GP. However, CA45-H GL L GL bound with high affinity to the endosomal form of GP (GP CL ), which might relate to augmented accessibility of the cognate epitope and/or subtle epitope conformational changes in GP CL without MLD and glycan cap. Use of GPDMuc immunogen cocktail lacking MLD in this study may have contributed to the elicitation of these rare B cell precursors. Recently, optimized HIV Env immunogens have been designed that, unlike wild-type Env, effectively elicit precursors of HIV-1 bNAbs (Jardine et al., 2013; McGuire et al., 2016; Sok et al., 2016) . The proteolytically remodeled GP CL represents a germline-targeting immunogen that could efficiently trigger CA45-like precursor B cells and lead to polyclonal cross protective responses at improved titers.
The prototypic ebolavirus neutralizing epitope, the so-called base epitope, is targeted by EBOV-specific antibodies such as KZ52 (Lee et al., 2008) , c2G4, and c4G7 (Murin et al., 2014) , as well as SUDV-specific mAbs 16F6 (Dias et al., 2011) . This epitope consists of residues at the GP1-GP2 interface within the base of the trimeric GP, with no cross-neutralizing mAb targeting this epitope previously reported. CA45 competes with base binders, targets the IFL, and contacts residues in both GP1 and GP2 with a footprint that partially overlaps the base epitope, while approaching GP at an angle tilted toward the tip of the IFL, as compared to KZ52 (Figures 4D and 5D ). The footprint of CA45 defines a conserved epitope ( Figure 4C ) encompassing (1) the b3 strand at the N terminus of GP1 as well as (2) b19 and b20 strands forming the stem of the IFL on GP2.
The most critical interaction residues within the CA45 epitope, R64, Y517, and G546, line up in a cluster along the IFL, between the KZ52 binding site and the fusion peptide (the IFL tip) (Figure 4D) . The ability to simultaneously bind both GP1 and GP2 is shared between CA45 and other described base binders. Interestingly, another IFL mAb, FVM02, that binds to the tip of IFL with no GP1 contact lacks neutralizing activity (Keck et al., 2015) , suggesting that clamping GP1 and GP2 at the trimer base may be critical for effective neutralization of ebolaviruses.
Despite the relationship between the CA45 and KZ52 epitope, the mechanistic differences between these two classes of antibodies are striking. CA45 appears to function at two levels: partially inhibiting the GP cleavage, an early critical step in filovirus entry, and blocking the virus entry post-cleavage while KZ52 is completely inactive after GP cleavage. These observations suggest a two-punch mechanism of action by CA45 on early and late stages of the entry process.
In the crystal structure of EBOV GP (5JQ3) (Zhao et al., 2016) , a cluster of residues within the cathepsin cleavage loop (D192/ F193/F194) hovers over the CA45 epitope. Alanine substitution of these residues enhanced GP binding to CA45, suggesting that these residues might restrict access to the CA45 epitope in the GP trimer. Interestingly, this region is not traceable in the GP CL structure, suggesting that it is either highly disordered or is removed by thermolysin (Bornholdt et al., 2016a) , possibly explaining the dramatically increased binding affinity of GP CL for both mature and germline CA45. Mutagenesis of these residues and cleavage by cathepsin might have similar effects on exposure of the CA45 epitope. The ability of this so-called DFF lid to block access to both the viral GP inhibitor toremifene (Zhao et al., 2016) and the CA45 binding epitope further suggests that this epitope is a major site of vulnerability and that CA45 and toremifene might be acting by a shared, yet to be defined, mechanism of action. In addition to the DFF lid, alanine substitution of the N40 glycosylation site (N40A and T42A) also increased CA45 binding. Collectively, these data further suggest that modifying the exposure of such epitopes may help expand the breadth of ebolavirus vaccines. Thus, future strategies aiming at expanding the bNAb memory B cells should focus on designing immunogens and regimens that enhance the epitope exposure and elicitation of such rare precursors. Such modifications could include deletion of MLD, removal of the glycan cap, and potentially further resurfacing to enhance the immunogen binding to precursors for other bNAbs, such as those binding to the RBS or the stalk. CA45, delivered at the peak of viremia, displayed full protective efficacy against EBOV infection in mice and 50% protection in a highly stringent EBOV guinea pig model. Given the distinct mechanisms of action of CA45 and FVM04 at different stages of the entry process, we hypothesized that a cocktail of the two mAbs targeting multiple steps of ebolavirus entry would be more effective. Consistent with this hypothesis, a cocktail of FVM04 and CA45 was fully protective in guinea pigs against EBOV. Similarly, the cocktail provided superior protective efficacy in an IFNAR À/À mouse model against wild-type (non-adapted) SUDV. In the guinea pig model of SUDV infection, CA45 alone was fully protective against GPA-SUDV. Furthermore, two doses of the CA45/ FVM04 cocktail were fully protective in BDBV-infected ferrets, evidenced by the lack of mortality and absence of all clinical and laboratory symptoms of the disease. Thus, this cocktail represents a post-exposure antibody therapeutic that is fully protective against all three highly pathogenic ebolaviruses.
During infection, ebolaviruses produce large amounts of sGP, the product of the unedited GP gene that lacks MLD and GP2 (de La Vega et al., 2015) . sGP is considered a decoy antigen that absorbs apex-binding antibodies. However, it is not clear whether sGP plays a direct role in pathogenesis (de La Vega et al., 2015) . Nevertheless, currently all antibody cocktails that significantly protected against EBOV in NHPs include an sGP binding antibody Pettitt et al., 2013; Qiu et al., 2016; Qiu et al., 2012; Qiu et al., 2014) . Thus, it remains enigmatic whether sGP binding is a positive or negative attribute of an immunotherapeutic cocktail targeting ebolaviruses. Our findings demonstrate that the addition of the cross-reactive sGP-binding mAb FVM04 significantly improves the protective efficacy against EBOV. It is possible that only the excess FVM04 unbound by sGP is responsible for improved efficacy. Alternatively, FVM04 might neutralize a yet to be defined function of sGP that could play a role in ebolavirus pathogenicity. A sGP-binding therapeutic mAb may also relieve the emerging apex-binding antibodies produced by the host, which could help control the infection.
In summary, we report a conserved ebolavirus neutralizing epitope exploited by NHP-derived bNAb CA45, which overlaps with the ebolavirus IFL. We further demonstrate that an antibody cocktail targeting this epitope together with the RBS can provide broad protection against all three ebolaviruses that have epidemic potential and high mortality in humans. Furthermore, we show that modifications of the GP immunogen enhancing accessibility of antigenic surfaces in the base region of GP can substantially augment the reactivity to bNAb CA45 and its inferred germline precursors, an important finding that can inform improved design of broadly protective filovirus vaccines.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Mouse Challenge Studies with EBOV All mice were healthy, immune competent and drug and test naive. Mice were housed in microisolater cages and provided chow and water ad libitum. 6-8 week old, female BALB/c mice were given 100 PFU of mouse-adapted EBOV (Mayinga) diluted in PBS, via the IP route. Littermates of the same sex were randomly assigned to experimental groups. Antibodies were administered IP at indicated time points and dosage. Control mice were given PBS. Mice were observed through day 21 for clinical signs of disease such as hypoactivity, reduced grooming, and weight loss. When signs of disease were noted, observations were increased to two times a day. Moribund and surviving mice were humanely euthanized accordingly to IACUC-approved criteria.
Mouse Challenge Studies with SUDV All mice were healthy but have an inherent immunodeficiency due to lack of IFNa receptor. All mice were drug and test naive. Mice were housed in microisolater cages and provided chow and water ad libitum. Male and female IFNAR À/À mice (4-5 weeks old) were exposed by IP infection to 1,000 PFUs of SUDV (Boniface) and treated with antibodies at indicated time points and doses. Littermates of the same sex were randomly assigned to experimental groups. Control mice were given PBS. Mice were observed for clinical signs of disease daily and moribund and surviving mice were humanely euthanized according to IACUC-approved criteria.
Guinea Pig Challenge Studies with EBOV and SUDV All guinea pigs were healthy and immune competent as per vendor's representation. All guinea pigs were drug and test naive. Animals were monitored daily for food and water consumption and given environmental enrichment according to the guidelines for the species. Cleaning of the animals was completed three times per week which included a complete cage and bedding material change. Animals were kept 2 or 3 per cage in the large shoe box cages from IVC Alternative Design. Each unit is ventilated with a HEPA blower system. 4-6 week old female Hartley guinea pigs (250-300 g) were randomly assigned to experimental groups and challenged via IP with a 1000 x LD 50 of guinea pig adapted EBOV or 1000 x LD 50 guinea pig adapted SUDV in 1 mL of DMEM. CA45 and/or FVM04 were given at indicated time points and doses, with 6 guinea pigs/group (n = 6). Control guinea pigs with 4 animals/group (n = 4), were given PBS treatment. Animal were observed for clinical signs of disease, survival and weight change for 15-16 days, while survival was monitored for an additional 12 days.
Ferrets Challenge Studies with BDBV
All ferrets were clinically free from symptoms of any contagious, infections, or communicable disease. Animals received rabies vaccine Imrab-3 when they reached 2-3 months old. All animals were drug and test naive. Animals were monitored daily for food and water consumption and given environmental enrichment according to the guidelines for the species. Cleaning of the animals was completed three times per week which included a complete cage and bedding material change. Animals were kept 2 or 3 per cage in the Allentown Caging system. Each unit was ventilated with a HEPA blower system. All units were autoclavable and stainless steel in structure. Ferret challenge studies were performed as previously described (Kozak et al., 2016) . Briefly, 6-month old male and female ferrets (Mustela putorius furo) (620-960 g) were infected by intramuscular route with 253 TCID 50 of Bundibugyo virus/ H.sapiens-wt/UGA/2007 (BDBV) (GenBank: KR063673.1). Group assignments were random for each sex. Antibody treatment was given to animals via IP route on 3 and 6 dpi. Animals were monitored daily and clinical scoring was recorded. Blood, oral, rectal swabs, and nasal wash samples were collected at À1, 3, 6, 10, 14, 21, and 27 dpi. Blood cell counts and serum chemistry assays were performed following the manufacturer's instructions using a VetScan HM5 hematology machine (Abaxis, USA) and VetScan VS2 analyzer (Abaxis, USA), respectively. Viral RNA was extracted using the QIAamp viral RNA mini kit (QIAGEN) following the manufacturer's instructions. Samples viral loads were determined using reverse transcription quantitative PCR (RT-qPCR) with an ABI StepOnePlus instrument as described previously (Kozak et al., 2016) . . HEK293T cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum and 100 I.U./mL penicillin and 100 mg/mL streptomycin. Vero and BHK-21 cells were cultured in Eagle's Minimum Essential Medium supplemented with 10% fetal bovine serum and 100 I.U./mL penicillin and 100 mg/mL streptomycin. U2OS cells were cultured in McCoy's 5a medium (GIBCO) supplemented with 10% fetal bovine serum and 100 I.U./mL penicillin and 100 mg/mL streptomycin. All cell lines were incubated at 37 C with 5% CO 2 .
Cell Lines
NHP PBMCs
The sera and PBMCs described in this study were collected from a cynomolgus macaque (macaque 20667, 3 years old male), who received three immunizations (on days 0, 28, and 56) with a mixture of filovirus GPDmuc. The animal was prescreened to ensure lack of exposure to Mycobacterium tuberculosis, Simian Immunodeficiency Virus (SIV), Simian T-Lymphotropic Virus-1 (STLV-1), Macacacine herpesvirus 1 (Herpes B virus), and Simian Retrovirus (SRV1 and SRV2) before immunization. Prior testing history of the NHP#20667 was unknown. The time point of the PBMCs used for the subsequent single B cell sorting was day 84, 28 days post the 3 rd immunization. Detailed information on these has been previously reported (Keck et al., 2015) .
Viruses
Recombinant Indiana VSV (rVSV) expressing filovirus GP were generated as previously described (Howell et al., 2016; Miller et al., 2012; Ng et al., 2014; Wong et al., 2010) . HEK293T cells were grown to 80% confluency before transfection with EBOV-GP pCAGGS, SUDV-GP pcDNA, or BDBV-GP pCAGGS using FuGENE HD (Promega). Cells were culture overnight at 37 C with 5% CO 2 .The next day, the media was removed and rVSV-G virus (kerafast) was used to infect the cells in DMEM at an MOI of 3 for 1 hr before washing the cells with 1X DPBS three times. DMEM supplemented with 2% fetal bovine serum and 100 I.U./mL penicillin and 100 mg/mL streptomycin was added to the infected cells and they were culture overnight as described above. The next day, the supernatant was harvest and clarified by centrifugation at 300xg for 10 min before aliquoting and storing at À80 C. To titrate the pseudotyped viruses, BHK-21 cells were seeded at 2.7x10 5 cells/mL in EMEM supplemented with 10% FBS and 100 I.U./mL penicillin and 100 mg/mL streptomycin in 6-well plates (Corning) overnight. The final volume was 3 mL per well. The next day, cells were 80% confluent and were transfected with VSV-G pCAGGS using FuGENE HD (Promega). Cells were culture overnight at 37 C with 5% CO 2 . The next day, the media was removed and a dilution of virus 10 À1 to 10 À8 in serum free EMEM was added to each well for 1 hr before layering each well with DMEM containing 0.9% agar. The agar was allowed to cool completely before returning plates to the incubator as described above. The next day, cells were fixed with 5% glutaraldehyde before removing agar and staining with crystal violet for 30 min. Afterward, the crystal violet was removed and plates washed with water before counting viral plaques. VSV pseudotypes with GP CL were generated by incubating rVSV pseudotype bearing full-length GP with 3x w/w thermolysin (Sigma) in 1X PBS for 1 hr at 37 C, followed by quenching with 1 mM phosphoramidon (Peptide International). Cleavage of GP was verified by SDS-PAGE.
METHOD DETAILS Isolation of MAbs by Single-Cell Sorting
Pan-ebola GP-specific memory B cell sorting and Ig encoding gene PCR amplification was performed following a previously described macaque single memory B cell sorting and cloning method with modifications (Sundling et al., 2012; Wang et al., 2016b) . Briefly, PBMC were incubated with a cocktail of antibodies to CD3 (APC-Cy7; SP34-2, BD PharMingen), CD8 (Pacific blue; RPA-T8, BD PharMingen), CD14 (BV605; M5E2, BD Horizon), CD20 (PE-Alexa Fluor 700; 2H7, VRC), CD27 (PE-Cy7; M-T271, BD PharMingen), IgG (FITC; G18-145, BD PharMingen), and IgM (PE-Cy5; G20-12, BD PharMingen), and Aqua blue (Invitrogen) to exclude dead cells. EBOV GPDmuc with His-tag and SUDV GPDmuc with HA-tag, produced in insect cell and mammalian 293F cells, respectively, were used to identify antigen-specific memory B cells at 4 mg/mL in the cocktail. After 1 hr of staining at 4 C, the cells were washed with cold PBS and 10 mL of each of anti-His-PE and anti-HA-APC (Miltenyi) were added in total volume of 100 mL for 1 hr at 4 C. Cross-reactive GP-specific memory B cells were sorted on a FACS Aria III cell sorter (BD Biosciences) to obtain single cells with the phenotype of CD20 + IgG + CD14 -Aqua Blue
Single cells were sorted into 96-well PCR plates containing lysis buffer followed by single B cell RT-PCR. We performed cloning and expression of IgGs using the previously described method (Tiller et al., 2008) .
Expression and Purification of Antibody, Fab Fragment, and GP Proteins
The genes of CA45 heavy chain, light chain, were cloned into IgG1 expression vectors, produced in FreeStyle 293F cells, and purified by protein A column (GE Healthcare Life Sciences) following the manufacturer's protocol as described previously (Wang et al., 2016b) . CA45 Fab was prepared by subcloning the heavy-chain gene into a Fab expression vector with an additional 6xHis-tag to the C terminus (Tran et al., 2014) . For Octet studies, CA45 Fab was generated from whole IgG using the Peirce Fab kit (ThermoFisher) according to the manufacturers' recommendations. CA45 was digested with agarose bound papain for 6 hr at 37 C before purification by Protein A column chromatography to remove undigested IgG and Fc from the reaction. The unbound fraction containing CA45 Fab was dialyzed overnight in PBS at 4 C before analysis by non-reducing SDS-PAGE. All proteins were further purified by size exclusion chromatography (SEC).
GP protein expression was performed as previously described (Howell et al., 2016) . EBOV, SUDV, RESTV, and BDBV full ectodomains (GPDTM) were expressed in Sf9 insect cells through baculovirus transfer vectors (pFastBac, Invitrogen). Constructs contained amino acids residues 1 to 605 followed by a C-terminal 6X histidine tag under the polyhedron late promotor and simian virus 40 (SV40) polyadenylation site. Bacmid DNA was generated by in vivo transpositions in E. coli and used to transfect Sf9 cells. The recombinant baculoviruses containing the GPDTM were recovered the supernatants and amplified in Sf9 cells. The resulting virus was used to infect Sf9 cells, and proteins were collected from the supernatants 3 days after infection. The supernatant was concentrated 10-fold and mixed with 2 mM CaCl 2 , 0.25 mM Ni 2+ , 20% glycerol, 10 mM imidazole, 0.5% Triton X-100, 1 M NaCl (final concentration), and pH adjusted to 7.2 with 5 N NaOH. Nickle beads (Ni Sepharose 6 FastFlow, GE Lifesciences) were added to the supernatants overnight at 4 C and then separated by centrifugation. The beads were resuspended and packed into a Bio-Rad Econo column and washed with buffer containing 10 mM imidazole. Proteins were eluted with 500 mM imidazole and proteins dialyzed against PBS with 10% glycerol, arginine, glutamic acid pH 7.4. For sGP production, the full coding sequence of sGP followed by a 6-histadine tag was expressed in 293T cells. The delta peptide was separated from sGP in the supernatant using a nickel column. The flow through containing only sGP was concentrated. All proteins were analyzed by bicinchoninic acid (BCA) assay, SDS-PAGE and western blot.
EBOV GP CL was produced by thermolysin cleavage of EBOV GPDTM as previously described (Hashiguchi et al., 2015) . A 3x amount w/w of thermolysin (Sigma) in 1X PBS was mixed with the GPDTM for 1 hr at 37 C, followed by quenching with 1 mM phosphoramidon (Peptide International). Cleavage of GP was verified by SDS-PAGE.
ELISA Binding Assays
Filovirus GPs lacking the transmembrane domain (GPDTM), EBOV GP CL , or EBOV sGP were coated onto 96-well Maxisorb ELISA plates at 100 ng/well diluted in DPBS overnight at 4 C. On the following day, the plates were washed three times with 300 mL of 1X DPBST (0.05% Tween-20) and blocked with StartingBlock Buffer (Thermo Scientific) for 1 hr at room temperature. After blocking, plates were washed as described above before adding CA45 diluted into 1X DPBST (0.05% Tween-20) at pH 7.5, 5.5 or 4.5 for 1 hr at room temperature. After incubation, plates were washed as described above and a 1:3000 dilution of goat anti-human-HRP (KPL) diluted in StartingBlock Buffer was added for 1 hr at room temperature before a final wash and the addition of 3,3 0 ,5,5 0 -Tetramethylbenzidine (TMB) substrate (Life Technologies) for 30 min. Plates were read at an optical density of 650 nm on a VersaMax plate reader. Softmax was used to fit the data to a 4PL curve.
BioLayer Interferometry
Kinetics experiments were performed using the ForteBio Octet Red96 platform. All data were collected at 25 C with orbital shaking at 1,000 rpm in 200 mL in 96-well black flat bottom plates (Greiner Bio-one). For CA45 IgG kinetics, reagents were diluted in 1X kinetics buffer (1X PBS, 0.01% BSA and 0.002% Tween-20) supplied by ForteBio. Protein G sensors (ForteBio) were equilibrated for 10 min in 1X kinetics buffer prior to loading with 5 mg/mL of CA45 for 2 min. After the loading step, a 30 s baseline in 1X kinetics buffer was established before association with a range of concentrations of GPDTM for EBOV, SUDV, BDBV, or RESTV or EBOV GP CL for 5 min. Following CA45 association with GP, there was a 10-minute of dissociation step in kinetics buffer. For CA45 Fab kinetics, all reagents were diluted in 100 mM sodium phosphate, 150 mM NaCl, 0.02% Tween-20 pH 6.0 to reduce non-specific binding. His-tagged EBOV GPDTM was loaded onto pre-wet Ni-NTA sensors (ForteBio) for 120 s, followed by a 60 s baseline and then association with a range of CA45 Fab concentrations. The association step was followed by a 10 min dissociation step. For all experiments, a reference sensor without ligand was used to account for nonspecific binding of analyte to the sensor. All data were fit globally to a 1:1 Langmuir binding model using data analysis software 9.0 (ForteBio).
rVSV GP-GFP Neutralization Assay For neutralization, rVSV-GP was incubated with mAbs in serial dilutions for 1 hr at room temperature before infecting a monolayer of Vero cells in 96-well plates. Infectivity of rVSVs were measured by counting eGFP-positive cells 12-14 hr post infection and normalized to control wells without antibody.
rVSV-GP Luciferase Neutralization Assay
Neutralization assays were performed as previously described (Howell et al., 2016) . Vero cells were seeded at 60,000 cells/well and cultured overnight in EMEM supplemented with 10% fetal bovine serum and 100 I.U./mL penicillin and 100 mg/mL streptomycin at 37 C and 5% CO 2 . The next day, a serial dilution of antibody was incubated with pseudotyped virus in serum free EMEM for 1 hr at room temperature before infecting Vero cells at an MOI of 0.04 at 37 C, 5% CO 2 for 1 hr. After infection, 50% v/v EMEM medium supplemented with 2% FBS, and 100 I.U./mL penicillin and 100 mg/mL streptomycin was added to cells. The next day, cells were lysed with Passive Lysis Buffer (Promega) for 30 min at room temperature before the addition of the Luciferase Activating Reagent (Promega). The luminesce was read immediately on a Biotek Plate reader. Percent neutralization was calculated based on wells containing virus only. Data were fit to a 4PL curve in GraphPad Prism 6.
Gene Family Usage of IgG Gene
The gene family usage of the variable region of the IgG heavy-and light-chains was analyzed using IgBlast (https://www.ncbi.nlm.nih. gov/igblast/) with KABAT as the V domain delineation system and a customized cynomolgus macaques Ig heavy-and light-chain germline database annotated based on the published cynomolgus macaques genomic dataset (Ebeling et al., 2011; Yan et al., 2011; Yu et al., 2016) .
CA45 Heavy-and Light-Chains Alanine Scanning A panel of 63 alanine (Ala) mutants of CA45 was generated, with each amino acid residue in the heavy chain and light chain complementarity-determining regions (CDRs; subdomain delineated by Kabat system through IgBlast as described above) substituted by Ala, with the exception of Ala residues already present in the WT sequence. Each mutant HC or LC was paired with their corresponding WT HC or LC and co-transfected into FreeStyle 293F cells, with the culture supernatants collected four days later for binding analysis.
The dilution factor of the Ala mutant supernatants has been optimized by pilot ELISA to reach OD450 value from 0.6-1.5. Maxisorp ELISA plates (Nunc) were coated with 2 mg/mL of GP proteins (EBOV, SUDV or BDBV) for detecting GP binding or AffiniPure Donkey anti-Human IgG, Fcg fragment (Jackson ImmunoResearch Labs) for normalizing IgG expression, respectively in PBS (pH 7.4) at 4 C overnight. After incubation with blocking buffer (BB, 2% non-fat milk, 5% FBS in PBS), the WT or mutant supernatant in 5-fold serial dilution in BB was added and incubated for 1 hr at 37 C. The secondary Ab, HRP-conjugated goat anti-human Fab (Jackson ImmunoResearch Labs), and TMB solution (Life Technologies) were used to develop signal. OD450 value for GP-bindings were normalized with corresponding IgG expression OD450 value, and relative GP binding affinity were calculated for each Ala mutant compared with the WT supernatant value.
Epitope Mapping of GP Using Alanine Scanning Mutagenesis A shotgun mutagenesis library of full-length EBOV GP (Mayinga-76) expressed in HEK293 cells was used to determine the critical GP residues for CA45 binding, as previously described (Howell et al., 2016) . In this library, clones with single point mutations spanning residues 33-767 are mutated to alanine (and alanine to serine). Clones are transfected into HEK293T cells in 384-well plates and allowed to express for 22 hr. Cells are then incubated with CA45 (or control antibodies) followed by a secondary antibody conjugated to Alexa Fluor 488. After washing cells, fluorescence is measured using Intellicyt high throughput flow cytometer (Intellicyt, Albuquerque, NM). Background fluorescence was subtracted from control wells, and mAb reactivity to each GP mutant was calculated relative to WT GP fluorescence.
Electron Microscopy, Image Processing, and 3D Reconstruction EBOV GPDTM was incubated with 6 molar excess of CA45 Fab overnight at 4 C. The complex was purified through an S200i SEC column (GE Healthcare). The sample was added to 400 square copper mesh grids coated with carbon and stained with 2% uranyl formate. The grids were imaged on a 120keV Tecnai Spirit electron microscope using a TemCam F416 4k x 4k CCD. Particles were selected from raw micrographs using DoGPicker ) through the Appion interface (Lander et al., 2009 ). Particles were then organized into stacks and aligned using iterative MRA/MSA (Ogura et al., 2003) . After making clean 2D stack of particles, EMAN2 (Tang et al., 2007) was used to refine a final 3D model. Crystal structures were docked into the reconstruction using UCSF Chimera (Pettersen et al., 2004) .
Cathepsin Cleavage Inhibition Assay
The viral envelope of rVSV-EBOV GP virions were labeled with biotin using a function-spacer-lipid construct (FSL-biotin) (Sigma-Aldrich) at neutral pH for 1 hr at 37 C, as described previously (Ng et al., 2014) . The labeled virus stock was then acidified to pH $5.5 by addition of 10X 2-[N-morpholino]ethanesulfonic acid (MES) buffer. Virions were diluted and aliquoted into a PCR plate. Biotin-labeled virions were pre-incubated with 1000 nM of test antibody for 1 hr at 37 C at pH 5.5. Virion-antibody complexes were then subjected to proteolysis by recombinant human Cathepsin L (R&D Systems) at 4 ng/mL for 30 min at 37 C. The reaction was stopped by the addition of E64 inhibitor (Peptides International) followed by dilution into 1X PBS buffer, pH 7.4. Samples were analyzed by western blot using h21D10 monoclonal antibody (Holtsberg et al., 2015) directly conjugated to horseradish peroxidase.
Live Cell Imaging
Live imaging was performed as previously described on a Zeiss AxioObserver.Z1 widefield epifluorescence microscope equipped with a heated environmental chamber, 40x/1.3NA objective, and DAPI/FITC/Texas Red/Cy5 filters (Spence et al., 2016) . Briefly, purified DiD-labeled VSV expressing full-length EBOV GP was incubated with 100 mg/mL CA45 in imaging buffer for 1 hr at 37 C. Virus was spinoculated at 4 C and 1500 x g for 20 min onto pre-chilled U2OS cell monolayers seeded on glass coverslip dishes (MatTek). Following the removal of unbound virus, dishes were immediately mounted in the microscope, and warm imaging buffer (140 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 20 mM HEPES, 5 mM glucose, 2 mg/mL Hoechst 33342, and 2% FBS, pH 7.4) was added to mark the start of experiments. Images were taken every 6 s over a two-hour period. To examine viral trafficking, antibody-treated DiD-labeled virus was spinoculated onto U2OS cells stably expressing monomeric NeonGreen-tagged NPC1. Cells were imaged live at 45 min after warming to 37 C. Data were compiled from three independent experiments, and co-localization analysis was performed using Volocity (Perkin Elmer) software as described previously (Spence et al., 2016) .
Analysis of Ebolavirus GP Variant Sequences
We downloaded ebolavirus GP variant sequences from ebolavirus database under NCBI virus variation resource (https://www.ncbi. nlm.nih.gov/genomes/VirusVariation/Database/nph-select.cgi?cmd=database&taxid=186536) using the following criteria: Select sequence type: Protein (Full-length sequences only: uncheck) Species: any Host: any Region/Country: any Genome region: Spike glycoprotein Isolation source: any Collapsed identical sequences: checked We initially recovered 1359 GP sequences, with 231 unique sequences remained for further analysis after the collapse and removal of identical sequences. Multiple sequence alignment of these 231 GP sequences was performed using MUSCLE version 3.8.31 (Edgar, 2004a, b) . The GP residues of interest were then inspected based on the GP sequence alignment, using EBOV Mayinga GP numbering system.
QUANTIFICATION AND STATISTICAL ANALYSIS
For animal studies, Kaplan Meier survival curves were analyzed with the log-rank (Mantel-Cox) test using Prism 6 software (GraphPad Software, La Jolla, CA). Individual animal experiments were performed with 10 mice per group (n = 10). In some instances, data from multiple experiments with identical conditions are combined in one Kaplan Meier curve and analyzed statistically (where indicated in figure legends with n > 10). For alanine scanning mutagenesis of GP the error bars represent the mean and range of at least two replicate data points. For ELISA and neutralization data each data point is represented as average of triplicates ± SD. For virus neutralization data, each data point represents the average of three wells run in triplicate ± SD.
DATA AND SOFTWARE AVAILABILITY
For evaluation of epitope conservation sequences for 1,300 ebolavirus GP variants were retrieved from the NCBI Virus Variation Database: https://www.ncbi.nlm.nih.gov/genomes/VirusVariation. The sequences of CA45 antibody reported in this paper have been deposited at GenBank (GenBank: KY859862, KY859863). The CA45 EM data have been deposited at EMDB (EMDB: EMD-8694). (A) FVM04 but not CA45, KZ52, or MR72 inhibit the interaction of GP CL with NPC-1 domain C (dC) determined in an ELISA based assay. (B) CA45 partially blocks the cleavage of GP to GP CL determined in vitro by using thermolysin. GP and GP CL were detected by western blot using a monoclonal antibody specific for the core GP1 (mAb21D10). (C) Lipid mixing of viral and endosomal membranes is inhibited by NH 4 Cl, KZ52 (100 mg/mL) but not CA45 (100 mg/mL) as determined by measuring viral dequenching using an in vivo imaging assay.
